Lymphoma Clinical Trials in New York State

Showing 481-497 of 497 trials

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

NCT00061672

The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.

Lymphoma, Non-HodgkinHodgkin's Lymphoma

Abbott67 participantsStarted Apr 2003

Phoenix, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +11 more locations

COMPLETEDPhase 286 miles

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

NCT00501735

This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia. This study is designed to assess objective response (OR) \[complete response (CR) or partial response (PR)\] in subjects with cutaneous manifestations of CTCL with a requirement for maintenance of such objective response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally, this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB, III, or IVA treated with oral forodesine.

Cutaneous T-cell Lymphoma (CTCL),

BioCryst Pharmaceuticals144 participantsStarted Jul 2007

Birmingham, Alabama, United States • Stanford, California, United States • New Haven, Connecticut, United States +38 more locations

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Lymphoma Trials in Other Cities

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in New York State